BDNF Val66Met and spontaneous dyskinesias in non-clinical psychosis

https://doi.org/10.1016/j.schres.2012.06.018Get rights and content

Abstract

Background

Evidence indicating that symptoms of non-clinical psychosis (NCP) occur in 6–8% of the general population suggests that psychosis may occur across a continuum. Although a number of studies have examined environmental contributors, to date there have been few investigations of biological/genetic factors in this integral population. A recent study observed spontaneous dyskinetic movements (reflecting an innervated striatal system) in individuals reporting NCP. The present investigation is designed to replicate this finding and determine if brain-derived neurotrophic factor (BDNF) (implicated in striatal dopamine function) is associated with dyskinesias.

Method

A total of 68 young-adult participants reporting High and Low-NCP were assessed for dyskinetic movements using a sensitive instrumental measure of force variability. Saliva from the participants was genotyped for val66met (rs6265), a common functional polymorphism of the BDNF gene (the Met allele is associated with lower activity-dependent release of BDNF).

Results

Participants in the High-NCP group showed significantly elevated levels of force variability. Met allele carriers exhibited significantly higher levels of force variability when compared with the Val homozygotes. Logistic regression indicated that the odds of membership in the High-NCP group were significantly higher given the presence of dyskinesias (OR = 2.32; CI: 1.25–4.28).

Conclusion

Findings of elevated force variability suggest that individuals with NCP exhibit subtle signs of striatal vulnerability, reflected more dramatically as jerking and hyperkinetic movements in patients with formal psychosis. The results are consistent with a larger literature implicating BDNF as a critical factor underlying abnormal movements, and suggest that specific candidate genes underlie putative markers across a psychosis continuum.

Introduction

An accumulating body of evidence indicating that symptoms of sub-clinical psychosis are experienced by the general population suggests that psychosis occurs as a continuous phenotype (Kelleher and Cannon, 2011). In a series of investigations, researchers have been working to understand the nature of vulnerability factors along this phenotypic continuum (Zammit et al., 2008, Blanchard et al., 2010, Jacobson et al., 2010, Alemany et al., 2011, Mackie et al., 2011, Mittal et al., 2011a, Mittal et al., in press, Macmanus et al., 2012). This line of study is integral as examining putative markers in an environment without the third variable confounds (e.g., medications, neurotoxicity) stands to significantly elucidate etiological factors underlying psychosis. As research continues to clarify the continuum of non-clinical psychosis (NCP; fleeting psychotic symptoms in the absence of illness, experienced by a proportion of the general population), an important next step lies in exploring the genotype of individuals on the non-clinical side of the spectrum. Although recent studies have shown support for familial clustering of NCP symptoms (Hanssen et al., 2006, Polanczyk et al., 2010), along with familial covariation of NCP symptoms with maternal schizophrenia spectrum disorder (Polanczyk et al., 2010), and greater concordance for NCP among monozygotic twins (when compared to dizygotic twins) (Lataster et al., 2009), to date there is a dearth of research focusing on contributing genes or loci (Kelleher and Cannon, 2011).

Within the context of understanding factors contributing to psychosis, spontaneous dyskinesias (e.g., writhing and jerking movements) are of particular interest, as these movements reflect an impaired basal ganglia circuitry, which is also implicated in the onset and maintenance of psychotic symptoms (DeLong and Wichmann, 2007). More specifically, researchers have observed that independent of medication status, increased spontaneous dyskinesias are a natural byproduct of the pathogenesis of schizophrenia (Puri et al., 1999, Cortese et al., 2005, Pappa and Dazzan, 2009, Mittal and Walker, 2010), and that these movements reflect dysregulated dopaminergic activity in the striatal region (DeLong and Wichmann, 2007). Following a line of research examining spontaneous movements in high risk youth (e.g., schizotypal personality disorder, prodromal syndromes) (Mittal and Walker, 2007, Mittal et al., 2007, Mittal et al., 2008, Mittal et al., 2010a, Mittal et al., 2010b), our group recently conducted an investigation designed to determine if young adults reporting NCP also exhibited subtle signs of dyskinesia (Mittal et al., 2011a). Using a highly sensitive instrumental measure of force variability (FV; a proximal measure for dyskinetic movements), we observed that youth reporting high-NCP showed elevated dyskinesias indicating that a continuum of striatal vulnerability also underlies the non-clinical side of the psychosis spectrum.

Brain-derived neurotrophic factor (BDNF) modulates molecular pathways and receptors implicated in movement regulation (Sokoloff et al., 2002, Caldeira et al., 2007, Guillin et al., 2007) and is important to functions such as neural plasticity and repair (Cotman and Berchtold, 2002, Woo et al., 2005, Knaepen et al., 2010). In addition, endogenous BDNF influences dopamine system homeostasis by regulating the release and uptake dynamics of pre-synaptic dopamine transmission (Bosse et al., 2012). A single nucleotide polymorphism (SNP) in the human BDNF gene at codon 66 (vall66met) has functional consequences in both healthy and clinical populations, as it leads to reduced activity induced by BDNF release from neuronal cells (Chen et al., 2008). For example, in a transgenic mouse model for Huntington's disease, researchers found that reduced endogenous BDNF was associated with degeneration of striatal projection neurons and advances the onset of motor dysfunction (Canals et al., 2004). Consistent with this evidence, Foltynie and colleagues (2009) observed that val66met was predictive of earlier onset of levodopa-induced dyskinesias in Parkinson's disease. BDNF has also been implicated in psychosis (Green et al., 2011) and research indicates that patients with dyskinetic movements have lower levels of plasma BDNF (Tan et al., 2005).

To date, there has been limited research studying candidate genes in individuals expressing NCP and to our knowledge no studies have examined the BDNF val66met in this population. The noted finding that individuals reporting sub-clinical psychosis also show subtle signs of dyskinesia (Mittal et al., 2011b), and a body of evidence supporting the notion that val66met is implicated in the pathophysiology of abnormal movements suggests that this SNP may be conferring a putative vulnerability in persons endorsing NCP. A total of 68 young adults reporting High or Low-NCP were assessed for dyskinetic movements and genotyped for BDNF val66met to replicate the noted earlier investigation (Mittal et al., 2011a) and to test the hypotheses that the Met allele carriers would exhibit significantly higher levels of dyskinesias.

Section snippets

Participants

All participants were young adults (mean age 19, range: 18–26), recruited through the Adolescent Development and Preventive Treatment (ADAPT) research program. Individuals in the undergraduate research pool (n = 1248) were given the Launay–Slade Hallucination Scale (Bentall and Slade, 1985), a questionnaire focusing on symptoms of non-clinical psychosis. The option to participate in the study was made available to those scoring in the top and bottom 10th percentile (scores of ≥ 23 or ≤ 3

Results

A total of 68 participants were partitioned into High-NCP (n = 39) and Low-NCP (n = 29) groups. There were no significant differences between the groups on demographic characteristics including gender, age, ethnicity, and parental education. In addition, there was no significant difference in nicotine use between the groups. A Kolmogorov–Smirnov test revealed that the target dyskinesia variable met assumptions for parametric analyses.

Discussion

An important review of the NCP literature recently spoke toward the necessity of studies examining contributing genes (Kelleher and Cannon, 2011) and, to our knowledge, this is one of the first genetic studies in this context. The present results replicate our earlier findings suggesting that an underlying striatal vulnerability is present in the non-clinical side of the psychosis phenotype (Mittal et al., 2011a). In addition, findings that the BDNF val66met SNP is associated with increased

Role of funding source

This work was supported by National Institutes of Health Grants R01MH094650 and MH087258 to Dr. Mittal.

Contributors

Dr. Mittal attained funding, conceptualized the study, conducted analyses, and drafted the manuscript. Dr. Smolen processed the genomic DNA, interpreted data, and drafted the manuscript. Mr. Dean helped to run the study, prepare data, and draft the manuscript. Mrs. Pelletier helped to collect and interpret data and to draft the manuscript. Ms. Lunsford-Avery helped to collect data, interpret results, and draft the manuscript. Ms. Smith helped to interpret the data and draft the manuscript.

Conflict of interest

There are no conflicts of interest to report.

Acknowledgments

There no acknowledgments.

References (68)

  • V.A. Mittal et al.

    Associations between spontaneous movement abnormalities and psychotic-like experiences in the general population

    Schizophr. Res.

    (2011)
  • V.A. Mittal et al.

    Abnormal movements are associated with poor psychosocial functioning in adolescents at high risk for psychosis

    Schizophr. Res.

    (2011)
  • M.J. Porritt et al.

    Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons

    Exp. Neurol.

    (2005)
  • P.G. Surtees et al.

    No association between BDNF Vall66Met polymorphism and mood status in a non-clinical community sample of 7389 older adults

    J. Psychiatr. Res.

    (2007)
  • Y.L. Tan et al.

    Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements

    Schizophr. Res.

    (2005)
  • M. van 't Wout et al.

    Emotional processing in a non-clinical psychosis-prone sample

    Schizophr. Res.

    (2004)
  • S. Zammit et al.

    Investigating if psychosis-like symptoms (PLIKS) are associated with family history of schizophrenia or paternal age in the ALSPAC birth cohort

    Schizophr. Res.

    (2008)
  • A.O. Ahmed et al.

    Latent structure of psychotic experiences in the general population

    Acta Psychiatr. Scand.

    (2012)
  • S. Alemany et al.

    Childhood abuse, the BDNF-Val66Met polymorphism and adult psychotic-like experiences

    Br. J. Psychiatry

    (2011)
  • M. Bak et al.

    Early trauma may increase the risk for psychotic experiences by impacting on emotional response and perception of control

    Acta Psychiatr. Scand.

    (2005)
  • E. Barkus et al.

    Cognitive and neural processes in non-clinical auditory hallucinations

    Br. J. Psychiatry

    (2007)
  • K.E. Bosse et al.

    Aberrant striatal dopamine transmitter dynamics in brain-derived neurotrophic factor-deficient mice

    J. Neurochem.

    (2012)
  • M.P. Caligiuri et al.

    Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study #394

    Psychopharmacology (Berl)

    (1997)
  • J.M. Canals et al.

    Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease

    J. Neurosci.

    (2004)
  • T.D. Cannon et al.

    Endophenotypes in the genetic analyses of mental disorders

    Annu. Rev. Clin. Psychol.

    (2006)
  • B. Cheeran et al.

    A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS

    J. Physiol.

    (2008)
  • Z.Y. Chen et al.

    Impact of genetic variant BDNF (Val66Met) on brain structure and function

    Novartis Found. Symp.

    (2008)
  • M.R. DeLong et al.

    Circuits and circuit disorders of the basal ganglia

    Arch. Neurol.

    (2007)
  • L.E. Duncan et al.

    A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry

    Am. J. Psychiatry

    (2011)
  • T. Foltynie et al.

    BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease

    J. Neurol. Neurosurg. Psychiatry

    (2009)
  • M.J. Green et al.

    Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis

    Mol. Psychiatry

    (2011)
  • O. Guillin et al.

    Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine

    Int. Rev. Neurobiol.

    (2007)
  • M. Hanssen et al.

    Evidence for instrument and family-specific variation of subclinical psychosis dimensions in the general population

    J. Abnorm. Psychol.

    (2006)
  • P.J. Harrison et al.

    Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

    Mol. Psychiatry

    (2005)
  • Cited by (12)

    • Motor behavior reflects reduced hemispheric asymmetry in the psychosis risk period

      2016, Schizophrenia Research
      Citation Excerpt :

      Handwriting is a highly specialized skill requiring motor coordination. Previous work in UHR samples notes that movement abnormalities typically precede the onset of psychosis and may be an early sign of abnormal brain development (Mittal et al., 2007a,b, 2010a,b, 2011, 2012, 2014; Walker et al., 1994). Archival studies suggest that early signs of abnormal fine and gross motor skill (i.e., dyspraxia) in children, also predict later development of psychosis (Schiffman et al., 2015).

    • Nicotine usage is associated with elevated processing speed, spatial working memory, and visual learning performance in youth at ultrahigh-risk for psychosis

      2014, Psychiatry Research
      Citation Excerpt :

      Nicotine usage was measured utilizing the Alcohol/Drug Use Scale (AUS/DUS) (Drake et al., 1996), a clinician-rating based inventory that measures frequency of tobacco use on a scale ranging from 0 (no use), 1 (occasionally), 2 (less than 10 per day), 3 (11–25 per day) and 4 (more than 25 per day). The measure has been widely used in a number of psychosis spectrum studies (Cannon et al., 2008; Mittal et al., 2011, 2012; Dean et al., 2014; Carol and Mittal, 2014) and shows excellent reliability (Long and Hollin, 2009; Moller and Linaker, 2010). Participants were administered the Wide Range Achievement Test-Word Reading Subtest Fourth Edition (WRAT) as a measure of general intelligence (Wilkinson and Robertson, 2006).

    • Striatal abnormalities and spontaneous dyskinesias in non-clinical psychosis

      2013, Schizophrenia Research
      Citation Excerpt :

      The B module of Structured Clinical Interview for DSM-IV Disorders (SCID) (Overall and Gorham, 1976) was administered to participants in both groups to ensure that participants with elevated psychosis would not be included as this could potentially confound results (no participants were excluded based on this criterion). To maximize the potential to recruit a normative sample (and not an extreme low NCP group as we had in previous studies; Mittal et al., 2012a, 2012b, 2012c; Pelletier et al., 2012) screening with the CAPE positive domain was not an inclusion/exclusion criteria for the healthy control group. The CAPE is a self-report questionnaire that measures the frequency of psychotic-like experiences on a four-item Likert scale including “Never”, “Sometimes”, “Often”, and “Nearly Always” (Stefanis et al., 2002).

    • Emotion recognition and social/role dysfunction in non-clinical psychosis

      2013, Schizophrenia Research
      Citation Excerpt :

      Scores on the BPRS range from 18 to 126. Based on methods established in our previous work (Mittal et al., 2012a, 2012b), a score of 4 (“moderate”) or higher on any item was grounds for exclusion, although as noted, it was not necessary to exclude any participants from the study. The Institutional Review Board approved the protocol and informed consent procedures.

    View all citing articles on Scopus
    View full text